Loading…
CapsoVision, Inc., a medical technology company, manufactures and markets endoscopic video imaging devices focused on internal imaging of the gastrointestinal system. The company offers CapsoCam Plus, a capsule endoscopy system for visualization of the small bowel mucosa in adults and children aged 2 years and above; and CapsoCam Colon for visualization of the colon and detection and measurement of polyps, as well as develops CapsoColon 3D for large intestines (colon). It also provides CapsoCloud cloud-based software-as-a-service ecosystem as an off-premises video access and download solution; CapsoView, a data access reading device for viewing capsule videos; CapsoAccess, a Capsule data access system; and CapsoRetrieve, a retrieval kit to recover the capsule using a magnetic wand, as well as capsule video reading services. The company serves gastrointestinal medical practices, clinics, and hospitals. It sells its products to distributor customers who resell products. The company was formerly known as Capso Vision Inc. and changed its name to CapsoVision, Inc. in May 2016. CapsoVision, Inc. was incorporated in 2005 and is headquartered in Saratoga, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $14M | $-25M | $-25M | $-23M | -190.9% | 15.3% | 27.2% |
| 2024 | $12M | $-19M | $-20M | $-20M | 15.4% | 20.5% | 76.0% |
| 2023 | $10M | $-11M | $-11M | $-12M | 10.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Revenue | 9.75 | 11.76 | 13.55 |
| Operating Revenue | 9.75 | 11.76 | 13.55 |
| Cost Of Revenue | 4.26 | 5.38 | 6.38 |
| Gross Profit | 5.49 | 6.38 | 7.17 |
| Operating Expense | 16.84 | 26.29 | 32.69 |
| Research And Development | 9.33 | 15.12 | 18.31 |
| Selling General And Administration | 7.50 | 11.17 | 14.38 |
| Total Expenses | 21.10 | 31.67 | 39.07 |
| Operating Income | -11.35 | -19.92 | -25.52 |
| Total Operating Income As Reported | -11.35 | -19.92 | -25.52 |
| EBITDA | -10.96 | -19.40 | -24.95 |
| Normalized EBITDA | -10.96 | -19.40 | -24.95 |
| EBIT | -11.35 | -19.92 | -25.52 |
| Interest Income | 0.05 | 0.03 | 0.27 |
| Net Interest Income | 0.05 | 0.03 | 0.27 |
| Other Non Operating Income Expenses | 0 | 0 | -0.04 |
| Other Income Expense | 0 | 0 | -0.04 |
| Interest Income Non Operating | 0.05 | 0.03 | 0.27 |
| Net Non Operating Interest Income Expense | 0.05 | 0.03 | 0.27 |
| Pretax Income | -11.29 | -19.89 | -25.29 |
| Tax Provision | 0.01 | 0.01 | 0.02 |
| Tax Rate For Calcs | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 |
| Net Income Continuous Operations | -11.30 | -19.90 | -25.32 |
| Net Income From Continuing And Discontinued Operation | -11.30 | -19.90 | -25.32 |
| Net Income From Continuing Operation Net Minority Interest | -11.30 | -19.90 | -25.32 |
| Net Income | -11.30 | -19.90 | -25.32 |
| Net Income Common Stockholders | -11.30 | -19.90 | -25.32 |
| Net Income Including Noncontrolling Interests | -11.30 | -19.90 | -25.32 |
| Normalized Income | -11.30 | -19.90 | -25.32 |
| Diluted NI Availto Com Stockholders | -11.30 | -19.90 | -25.32 |
| Basic Average Shares | 38.62 | 46.34 | 46.87 |
| Diluted Average Shares | 38.62 | 46.34 | 46.87 |
| Reconciled Depreciation | 0.39 | 0.52 | 0.57 |
| Reconciled Cost Of Revenue | 4.26 | 5.38 | 6.38 |
| General And Administrative Expense | 1.97 | 4.21 | 6.85 |
| Other Gand A | 1.97 | 4.21 | 6.85 |
| Selling And Marketing Expense | 5.53 | 6.97 | 7.53 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| CapsoVision, Inc.this co. | CV | $377M | -14.88 | 28.41 | -190.9% | -14.73 |
| OmniAb, Inc. | OABI | $386M | -5.95 | 1.44 | -24.3% | -8.06 |
| Compass Therapeutics, Inc. | CMPX | $384M | -5.77 | 1.95 | -33.8% | -5.08 |
| Benitec Biopharma Inc. | BNTC | $380M | -10.01 | 3.90 | -39.0% | -6.83 |
| Viemed Healthcare, Inc. | VMD | $377M | 25.26 |
| 2.67 |
| 10.6% |
| 7.36 |
| Vanda Pharmaceuticals Inc. | VNDA | $376M | - | 1.15 | -67.4% | - |
| Lexeo Therapeutics, Inc. | LXEO | $375M | -3.75 | 1.52 | -40.5% | -3.28 |
| Delcath Systems, Inc. | DCTH | $372M | 137.96 | 3.35 | 2.4% | 327.03 |
| Perspective Therapeutics, Inc. | CATX | $371M | -3.59 | 1.79 | -49.8% | -3.41 |
| Peer Median | - | -3.75 | 1.87 | -36.4% | -3.41 | |